F 991

Drug Profile

F 991

Latest Information Update: 16 Nov 2010

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Fornix BioSciences; Utrecht University
  • Class Antiasthmatics; Immunotherapies; Peptides; Skin disorder therapies
  • Mechanism of Action Immunoglobulin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Allergic asthma; Crohn's disease; Multiple sclerosis; Skin disorders

Most Recent Events

  • 04 Oct 2007 F 991 licensed to Clinquest Group
  • 17 Feb 2005 F 991 is available for licensing (http://www.fornix.nl)
  • 16 Feb 2005 Phase-II clinical trials in Allergic asthma in Netherlands (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top